Market closedNon-fractional

Kyverna Therapeutics/KYTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Kyverna Therapeutics

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Ticker

KYTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Emeryville, United States

Employees

100

KYTX Metrics

BasicAdvanced
$331M
Market cap
-
P/E ratio
-$11.90
EPS
-
Beta
-
Dividend rate
$331M
17.173
16.913
1.975
3.005
-423.63%
0.92
0.92
-0.725

What the Analysts think about KYTX

Analyst Ratings

Majority rating from 4 analysts.
Buy

KYTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$27M
29.13%
Profit margin
0.00%
NaN%

KYTX Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 33.33%
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Actual
-$26.86
-$1.12
-
Expected
-$3.23
-$0.84
-$0.74
Surprise
732.44%
33.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Kyverna Therapeutics stock?

Kyverna Therapeutics (KYTX) has a market cap of $331M as of July 06, 2024.

What is the P/E ratio for Kyverna Therapeutics stock?

The price to earnings (P/E) ratio for Kyverna Therapeutics (KYTX) stock is 0 as of July 06, 2024.

Does Kyverna Therapeutics stock pay dividends?

No, Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders as of July 06, 2024.

When is the next Kyverna Therapeutics dividend payment date?

Kyverna Therapeutics (KYTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Kyverna Therapeutics?

Kyverna Therapeutics (KYTX) does not currently have a Beta indicator.

Buy or sell Kyverna Therapeutics stock

Buy or sell Kyverna Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing